Live data · NADAC + Part D CY24 · reviewed daily

Nilutamide (Nilandron)

Androgen Receptor Inhibitor class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2013-07-15
Generic availableYes · 1 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.4M in CY2024 Part D spend406 claims · 78 beneficiaries · 329 plans surveyed

Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
37 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Nilutamide used for?

Nilutamide is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Nilutamide?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Nilutamide?

NADAC pricing data not currently available for this drug.

Is Nilutamide on the FDA shortage list?

Nilutamide has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.